相关实验视频
Updated: May 23, 2025
09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.3K
脑内膜损害了临床前阿尔茨海默病的短期记忆结合
Lara Huyghe1, Lisa Quenon1,2, Yasmine Salman1
1Institute of Neuroscience (IoNS), UCLouvain, Brussels, Belgium.
概括
视觉记忆结合障碍是阿尔茨海默病 (AD) 的早期迹象,在显著的记忆丧失之前可以检测到. 这种缺陷与内皮层 (EC) 中的病理有关.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 耳内皮质 (EC) 是阿尔茨海默氏病 (AD) 中陶氏病理影响的第一个大脑区域.
- 对于EC的确切功能及其早期参与阿尔茨海默氏症病原体的理解尚不完全.
- 记忆绑定,一个关键的EC功能,可以使用视觉短期记忆绑定测试 (VSTMBT) 进行评估.
研究的目的:
- 确定VSTMBT的表现是否可以识别AD临床前阶段的个体.
- 为了研究VSTMBT性能,粉样蛋白 (Aβ) 病理和内皮层 (EC) tau负担之间的关系.
主要方法:
- 94名参与者,包括具有不同Aβ和tau状态的认知正常 (CN) 和轻度认知障碍 (MCI) 个体,接受了VSTMBT (仅形状条件 (SOC) 和形状颜色结合条件 (SCBC)).
- 进行了标准的神经心理评估 (PACC5),Aβ正子发射断层扫描 (PET) 和[18F]-MK-6240-PET扫描.
- 参与者被分为Aβ阴性CN,Aβ阳性CN (临床前AD) 和Aβ阳性MCI (prodromalAD) 组.
主要成果:
- 患有临床前AD (Aβ+CN) 个体在SCBC中表现不佳,与Aβ阴性CN参与者相比.
- 在欧共体中,SCBC的表现在很大程度上是由tau负担预测的,这是独立于其他因素的.
- 在检测患有临床前阿尔茨海默病的个体和阳性陶PET扫描时,SCBC表现出比PACC5更高的敏感性.
结论:
- 视觉短期记忆结合的缺陷存在于零星AD的临床前阶段.
- 损坏的SCBC性能与病理有关,特别是在内皮层内.
- 该SCBC显示潜力作为一个敏感的工具,用于检测早期EC tau病理在认知正常的个体.
相关概念视频
01:03Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
01:26Alzheimer's Disease: Overview
409
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
409
01:22Alzheimer's Disease: Treatment
141
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
141
01:19Role of Hippocampus in Memory
121
The hippocampus, a critical brain structure, plays an essential role in memory processing, particularly in the formation and retrieval of memory. This small, seahorse-shaped region is located within the medial temporal lobe, with one hippocampus in each brain hemisphere. Experimental studies involving lesions in the hippocampi of rats have demonstrated significant impairments in tasks such as object recognition and maze navigation, indicating the hippocampus involvement in both recognition and...
121